Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 22.5 %

NASDAQ EGRX opened at $0.98 on Friday. The business’s fifty day moving average is $0.68 and its two-hundred day moving average is $2.40. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $6.81.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC purchased a new stake in Eagle Pharmaceuticals during the second quarter valued at about $971,000. Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals in the 3rd quarter valued at approximately $96,000. Creative Planning purchased a new stake in shares of Eagle Pharmaceuticals in the 3rd quarter valued at approximately $59,000. Vanguard Personalized Indexing Management LLC acquired a new position in Eagle Pharmaceuticals in the 2nd quarter worth approximately $76,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Eagle Pharmaceuticals during the 2nd quarter worth approximately $65,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.